AMENDED AND RESTATED ASSET PURCHASE AGREEMENT January 13, 2016Asset Purchase Agreement • August 25th, 2016 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledAugust 25th, 2016 Company Industry JurisdictionThis AMENDED AND RESTATED ASSET PURCHASE AGREEMENT is made by and between (i) Lantheus MI Canada, Inc., a Canadian corporation (“Seller”), on the one hand, and (ii) Isologic Innovative Radiopharmaceuticals Ltd., a Canadian corporation (“Buyer”), on the other hand, amends and restates in its entirety the original Asset Purchase Agreement by and between Seller and Buyer executed as of December 31, 2015 (the “Execution Date”) and made effective only as of January 7, 2016 (this “Agreement”).
AMENDED AND RESTATED ASSET PURCHASE AGREEMENT January 13, 2016Asset Purchase Agreement • May 3rd, 2016 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledMay 3rd, 2016 Company Industry JurisdictionThis AMENDED AND RESTATED ASSET PURCHASE AGREEMENT is made by and between (i) Lantheus MI Canada, Inc., a Canadian corporation (“Seller”), on the one hand, and (ii) Isologic Innovative Radiopharmaceuticals Ltd., a Canadian corporation (“Buyer”), on the other hand, amends and restates in its entirety the original Asset Purchase Agreement by and between Seller and Buyer executed as of December 31, 2015 (the “Execution Date”) and made effective only as of January 7, 2016 (this “Agreement”).